重组人干扰素α-2b凝胶联合保妇康栓治疗宫颈高危型HPV感染的临床分析

Clinical analysis of recombinant human interferon α-2b gel combined with Baofukang suppository in the treatment of cervical high-risk HPV infection

目的探讨宫颈高危型人乳头瘤病毒(HPV)感染患者予以重组人干扰素α-2b凝胶联合保妇康栓治疗的效果。方法800例宫颈高危型HPV感染患者作为研究对象,随机分为对照组和研究组,每组400例。对照组患者实施重组人干扰素α-2b凝胶治疗,研究组患者予以重组人干扰素α-2b凝胶联合保妇康栓治疗。比较两组患者治疗前后血清炎性因子指标[白细胞介素-6(IL-6)、转化生长因子-β_(1)(TGF-β_(1))、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)]水平,治疗后临床症状(腰酸、白带增多、瘙痒以及尿痛)改善时间,临床疗效,HPV转阴率及不良反应发生情况。结果治疗前,两组患者的IL-6、TGF-β_(1)、TNF-α、hs-CRP水平比较差异无统计学意义(P>0.05);治疗后,两组患者的IL-6、TGF-β_(1)、TNF-α、hs-CRP水平均显著低于治疗前,研究组患者的IL-6(61.02±10.18)ng/L、TGF-β_(1)(16.88±2.82)ng/L、TNF-α(1.56±0.24)ng/L、hs-CRP(7.13±1.02)mg/L均显著低于对照组的(129.78±10.78)ng/L、(36.87±4.58)ng/L、(2.41±0.28)ng/L、(9.21±1.56)mg/L,差异具有统计学意义(P<0.05)。研究组患者的腰酸、白带增多、瘙痒以及尿痛改善时间分别为(6.32±1.13)、(5.95±1.06)、(5.35±0.96)、(4.96±0.86)d,均显著短于对照组的(7.42±1.24)、(6.82±1.14)、(6.24±1.05)、(5.74±1.14)d,差异具有统计学意义(P<0.05)。研究组患者的总有效率为94.75%,显著高于对照组的79.50%,差异具有统计学意义(P<0.05)。研究组患者的HPV转阴率为92.25%,显著高于对照组的71.75%,差异具有统计学意义(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论对宫颈高危型HPV感染患者予以重组人干扰素α-2b凝胶联合保妇康栓治疗疗效显著,有助于抑制患者炎症扩散,促进HPV尽快清除,有利于患者转归,且安全性高,值得推广应用。

Objective To discuss the effect of recombinant human interferonα-2b gel combined with Baofukang suppository in the treatment of cervical high-risk human papillomavirus(HPV)infection.Methods A total of 800 patients with cervical high-risk HPV infection were randomly divided into control group and research group,with 400 cases in each group.The control group was treated with recombinant human interferonα-2b gel,and the research group was treated with recombinant human interferonα-2b gel and Baofukang suppository.Both groups were compared in terms of levels of serum inflammatory factors[interleukin-6(IL-6),transforming growth factor-β_(1)(TGF-β_(1)),tumor necrosis factor-α(TNF-α),high-sensitivity C-reactive protein(hs-CRP)]before and after treatment,the improvement time of clinical symptoms(soreness of waist,increased leucorrhea,pruritis and dysuria)after treatment,clinical efficacy,negative conversion rate of HPV,and the occurrence of adverse reactions.Results Before treatment,there were no statistically significant differences in the levels of IL-6,TGF-β_(1),TNF-αand hs-CRP between the two groups(P>0.05).After treatment,the levels of IL-6,TGF-β_(1),TNF-αand hs-CRP in the two groups were significantly lower than those before treatment in this group;the research group had IL-6 of(61.02±10.18)ng/L,TGF-β_(1) of(16.88±2.82)ng/L,TNF-αof(1.56±0.24)ng/L and hs-CRP of(7.13±1.02)mg/L,which were significantly lower than those of(129.78±10.78)ng/L,(36.87±4.58)ng/L,(2.41±0.28)ng/L and(9.21±1.56)mg/L in the control group;the differences were statistically significant(P<0.05).The improvement time of soreness of waist,increased leucorrhea,pruritis and dysuria in the research group were(6.32±1.13),(5.95±1.06),(5.35±0.96)and(4.96±0.86)d,which were significantly shorter than those of(7.42±1.24),(6.82±1.14),(6.24±1.05)and(5.74±1.14)d in the control group,and the differences were statistically significant(P<0.05).The total effective rate of the research group was 94.75%,which was significantly higher than that of 79.50%of the control group,and the difference was statistically significant(P<0.05).The negative conversion rate of HPV in the research group was 92.25%,which was significantly higher than that of 71.75%in the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion For patients with cervical high-risk HPV infection,recombinant human interferonα-2b gel combined with Baofukang suppository can achieve significant efficacy,which can help to inhibit the spread of inflammation in patients,promote the elimination of HPV as soon as possible,and is beneficial to the outcome of patients.It has high safety,and is worthy of promotion and application.